Navigation Links
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors

MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and contributions in the public and private sectors of the life sciences industry, including as co-founder and Chief Executive Officer of Chiron Corporation (now Novartis).

Dr. Penhoet is currently the President of the Gordon and Betty Moore Foundation, overseeing the philanthropic activities of the Foundation since 2004. Dr. Penhoet has also held the position of Director with Alta Partners, a venture capital partnership investing in life science companies, since 2000. From 1998 to 2002, he served as Dean of the School of Public Health at the University of California, Berkeley. In 1981, Dr. Penhoet co-founded Chiron Corporation and served as its Chief Executive Officer until 1998. Prior to founding Chiron, he was a faculty member of the Biochemistry Department of U.C. Berkeley. Dr. Penhoet also serves as the Vice Chairman of the Independent Citizen's Oversight Committee of the California Institute for Regenerative Medicine which was created by the passage of Proposition 71, also known as the stem cell initiative.

A member of the Institute of Medicine of the National Academies of Sciences and a member of the American Society of Biological Chemists, Dr. Penhoet has co-authored more than 50 scientific articles and papers. In addition to ChemoCentryx, he serves as a Director of Zymogenetics, Scynexis, Metabolex and Renovis, Inc.

Dr. Penhoet earned his A.B. in biology from Stanford University, and his Ph.D. in biochemistry from the University of Washington. He was a post-doctoral fellow at the University of California, San Diego.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a multi-national clinical trial, called PROTECT-1, for patients with moderate-to-severe Crohn's disease. For more information, please refer to

ChemoCentryx believes that certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to (i) that ChemoCentryx anticipates incurring significant losses for the foreseeable future, (ii) dependence on the success of Traficet-EN(TM); (iii) delays in obtaining or a failure to obtain regulatory approval for product candidates, (iv) failure of any approved product to achieve significant commercial acceptance in the medical community or receive reimbursement by third-party payors, (v) the timing, success and cost of preclinical research and clinical studies, (vi) the timing, acceptability and review periods for regulatory filings, (vii) the availability of corporate partners, (viii) uncertainties relating to patent protection and intellectual property rights, (ix) the impact of competitive products and technological changes, (x) competition from other pharmaceutical or biotechnology companies, (xi) the availability of capital and the cost of capital, (xii) other vagaries in the biotechnology industry and (xiii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements to conform the statement to actual results or changes in the Company's expectations.

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
2. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
3. LifeVantage Corporation Appoints Industry Veteran David Brown as President & CEO
4. Crdentia Appoints Debbie Griffith to Director of Business Development, Reporting Directly to CEO
5. WellPoint Appoints Brian A. Sassi as President and CEO of the Companys Consumer Business Unit
6. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
7. Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer
8. China Sky One Medical Appoints Independent Auditor
9. Genstar Capital Appoints Mark Hanson to Managing Director
10. Casey Family Programs Appoints New Board Members
11. Casey Family Programs Appoints Dr. America Bracho as New Board Member
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... During the National ... caregivers and held two webinars on topics of ‘Medical and Palliative Care Decisions,’ ... at . , With a loved one's diagnosis of mesothelioma, the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... . The directory is specialized and only includes chiropractic clinics in the US. ... competent and trustworthy alternative health practitioner when back pain sets in. When people ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort ... the Word of Life Christian Church of Flint, MI, hosted a family-oriented evening ... 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever Recovery, a ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Foundation kicked off its annual fundraising campaign to raise funds for its research, ... raises approximately 10% of the organization’s annual funding. , The Mesothelioma Applied Research ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
(Date:11/30/2015)... , November 30, 2015 global cell ... of US$6.1 bn to US$11.3 bn by 2022 at a CAGR ... is expected to grow from its 2013 value of US$6.1 bn ... --> Transparency Market Research has announced the release of ... According to the report, titled ,Cell Culture Market - Global Industry ...
(Date:11/30/2015)... and BOCA RATON, Fla. , ... the Commercialization of Public Research (the Institute) announced ... KynderMed , a medical device start-up company with ... new company creation based on publicly-funded research, and bridges ... Florida -based universities and research institutions. ...
Breaking Medicine Technology: